Teropavimab

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

HIV-1 InfectionHIV Infections

165 competitors in HIV-1 Infection

#DrugCompanyPhaseTrials

1

Sunlenca

Gilead

Phase 3

52

Norvir

AbbVie

Phase 3

33

Tivicay

GSK

Phase 3

24

Biktarvy

Gilead

Phase 3

15

Invirase

Roche

Phase 3

16

FTC/TDF

Gilead

Phase 3

27

F/TAF

Gilead

Phase 3

18

F/TDF

Gilead

Phase 3

19

Focetria

CChiltern Pesquisa Clinica Ltda

Phase 3

110

Entyvio

Takeda

Phase 2

—Show 29 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

HIV-1 infection3 trials

A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection

Active, not recruiting·Gilead·Phase 2·NCT05729568·83 enrolled

Study to Evaluate the Safety and Efficacy of Teropavimab and Zinlirvimab in Combination With Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection

Completed·Gilead·Phase 1·NCT04811040·32 enrolled

A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to a Regimen of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir Twice-Yearly in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens

Not yet recruiting·Gilead·Phase 3·NCT07683000·590 enrolled

HIV Infections1 trial

A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to Long-acting Antiretroviral Therapy of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination With the Capsid Inhibitor Lenacapavir Twice-Yearly Versus Cabotegravir and Rilpivirine Every 8 Weeks in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy

Not yet recruiting·Gilead·Phase 3·NCT07682961·590 enrolled

Details

Drug Info

Related News